Evidence map›Paper›PMID 40841912›Full record

ReviewJournal of experimental & clinical cancer research : CR2025

A new era in cancer therapy: targeting the Proteasome-Bcl-2 axis.

Sourabh Soni, Vandana Anang, Yutong Zhao, Jeffrey C Horowitz, Richard S Nho, Yohannes A Mebratu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Anoikis in cancer: molecular mechanisms, resistance, and therapeutic strategies.Apoptosis : an international journal on programmed cell death · 2026
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sourabh SoniDepartment of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Davis Heart and Lung Institute, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Vandana AnangDepartment of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Davis Heart and Lung Institute, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Yutong ZhaoDepartment of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Davis Heart and Lung Institute, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Jeffrey C HorowitzDepartment of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Davis Heart and Lung Institute, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Richard S NhoDepartment of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Davis Heart and Lung Institute, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Richard.Nho@osumc.edu.
Yohannes A MebratuDepartment of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Davis Heart and Lung Institute, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Yohannes.Mebratu@osumc.edu.

Funding

The role of Bik in the replication and severity of influenza A virusR01AI148180 · NIAID · OHIO STATE UNIVERSITY · PI MEBRATU, YOHANNES AFEWORK · 2021 to 2025
$2.1M
Hypoxia-induced aberrant lactate generation and shuttling serves as a direct signal to promote pro-fibrotic fibroblast phenotypesR01HL171164 · NHLBI · OHIO STATE UNIVERSITY · PI Jeffrey C Horowitz, Richard S. Nho · 2025 to 2026
$1.5M
The Role of Ariadne RBR E3 ubiquitin protein ligase 2 (ARIH2) in influenza A virus replication and pathogenesis in the airway epithelial cellsR01AI187330 · NIAID · OHIO STATE UNIVERSITY · PI Yohannes Afework Mebratu · 2025 to 2026
$1.1M
NHLBI NIH HHS R01 HL171164NIAID NIH HHS R01 AI148180NIAID NIH HHS R01 AI187330NIH HHS HL171164NIH HHS HL17664NIH HHS R01AI148180The Ohio State University PG100125
6 · The paper itself

Abstract

The B-cell lymphoma-2 (Bcl-2) family proteins, key regulators of apoptosis, are frequently dysregulated in cancer, tipping the balance of cell survival and apoptosis in favor of survival. The ubiquitin-proteasome system (UPS) is a critical cellular machinery that controls the Bcl-2 levels through regulation of protein stability. This review delves into the intricate interplay between the proteasome and Bcl-2 family members, exploring how proteasome-mediated degradation impacts cell survival and proliferation to influence cancer progression. We discuss the therapeutic potential of targeting the proteasome-Bcl-2 axis, including the use of proteasome inhibitors as anticancer agents. We examine their mechanisms of action, clinical efficacy, and limitations while exploring emerging strategies to overcome these challenges.

Indexed as

Antineoplastic AgentsNeoplasmsProteasome Endopeptidase ComplexProteasome InhibitorsProto-Oncogene Proteins c-bcl-2AnimalsHumansMolecular Targeted TherapySignal TransductionAntineoplastic AgentsProteasome Endopeptidase ComplexProteasome InhibitorsProto-Oncogene Proteins c-bcl-2ApoptosisBcl-2 family proteinsCancerProteasome inhibitorsTherapeutic potentialUbiquitinationUbiquitin-proteasome system (UPS)

Identifiers

PMID40841912
PMCPMC12369272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.